Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi Sells 5,771 Shares

Phreesia, Inc. (NYSE:PHRGet Free Report) CFO Balaji Gandhi sold 5,771 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $30.04, for a total transaction of $173,360.84. Following the completion of the transaction, the chief financial officer now directly owns 105,514 shares in the company, valued at $3,169,640.56. This trade represents a 5.19 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Balaji Gandhi also recently made the following trade(s):

  • On Thursday, February 13th, Balaji Gandhi sold 28,759 shares of Phreesia stock. The shares were sold at an average price of $30.00, for a total transaction of $862,770.00.
  • On Monday, January 27th, Balaji Gandhi sold 4,813 shares of Phreesia stock. The shares were sold at an average price of $27.48, for a total value of $132,261.24.
  • On Tuesday, January 21st, Balaji Gandhi sold 5,827 shares of Phreesia stock. The stock was sold at an average price of $27.31, for a total value of $159,135.37.
  • On Wednesday, January 15th, Balaji Gandhi sold 836 shares of Phreesia stock. The shares were sold at an average price of $26.98, for a total value of $22,555.28.
  • On Monday, January 6th, Balaji Gandhi sold 3,195 shares of Phreesia stock. The shares were sold at an average price of $26.61, for a total value of $85,018.95.

Phreesia Trading Down 4.0 %

Phreesia stock opened at $28.49 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. The firm has a 50-day moving average of $27.22 and a 200-day moving average of $23.80. The company has a market cap of $1.66 billion, a price-to-earnings ratio of -19.38 and a beta of 0.96. Phreesia, Inc. has a one year low of $17.07 and a one year high of $30.53.

Phreesia (NYSE:PHRGet Free Report) last announced its quarterly earnings data on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. The company had revenue of $106.80 million during the quarter, compared to the consensus estimate of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The company’s quarterly revenue was up 16.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.58) EPS. On average, equities analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Institutional Trading of Phreesia

Hedge funds have recently added to or reduced their stakes in the company. Johnson Financial Group Inc. raised its stake in Phreesia by 381.3% in the 4th quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company’s stock worth $28,000 after purchasing an additional 896 shares in the last quarter. R Squared Ltd acquired a new position in Phreesia in the fourth quarter valued at about $30,000. International Assets Investment Management LLC boosted its holdings in shares of Phreesia by 2,179.7% in the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after purchasing an additional 1,395 shares in the last quarter. BankPlus Trust Department acquired a new stake in Phreesia in the fourth quarter valued at about $34,000. Finally, Quarry LP lifted its holdings in shares of Phreesia by 210.9% in the fourth quarter. Quarry LP now owns 2,835 shares of the company’s stock worth $71,000 after acquiring an additional 1,923 shares during the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $30.00 target price on shares of Phreesia in a research note on Tuesday, December 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 price objective on shares of Phreesia in a research note on Friday, January 10th. Robert W. Baird decreased their target price on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Truist Financial raised their price target on Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Finally, Citigroup boosted their price objective on Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Thirteen research analysts have rated the stock with a buy rating, According to data from MarketBeat, Phreesia presently has a consensus rating of “Buy” and a consensus target price of $31.15.

Check Out Our Latest Analysis on PHR

About Phreesia

(Get Free Report)

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

See Also

Insider Buying and Selling by Quarter for Phreesia (NYSE:PHR)

Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.